Global Search

Search articles, concepts, and chapters

Medeiros Felipe A

🇴🇲 University of Miami
ORCIDOpenAlex241 articles in GJC

241 articles in GJC

1.

Identification of Risk Factors for Glaucoma Progression in Free-Text Clinical Notes Using a Local Large Language Model.

Bhatnagar Anshul, Scherer Rafael, Samico Gustavo A, Muralidhar Rohit, Gutkind Naomi E, Palazoni Vitoria et al.

Transl Vis Sci TechnolMay 20260 citationsObservational Study

A medical LLM accurately identified glaucoma medication non-adherence, visit non-adherence, and family history from clinical notes, enabling large-scale research into these crucial risk factors.

8.

Retinal Ganglion Cell Loss and Patterns of Neuroretinal Rim Thinning at the Onset of Visual Field Defects in Glaucoma.

Rabinowitz Aaron Samuel, Vilasboas-Campos Verônica, Filho Marcus Guerreiro, Medeiros Felipe A

Am J OphthalmolSep 20250 citationsCohort Study

This study found diffuse optic rim thinning at early visual field defect onset indicates significantly more retinal ganglion cell loss than localized thinning, highlighting the importance of structural assessment for early glaucoma.

15.

Social history and glaucoma progression: the effect of body mass index, tobacco and alcohol consumption on the rates of structural change in patients with glaucoma.

Youssif Asmaa A, Onyekaba Ndidi-Amaka, Naithani Rizul, Abdelazeem Khaled, Fathalla Ahmed M, Abdel-Rhaman Mohamed S et al.

Br J OphthalmolNov 20242 citationsCohort Study

This study found higher BMI was linked to slower glaucoma progression, while tobacco and alcohol use had no significant effect on retinal nerve fiber layer loss. Underweight patients progressed faster.

24.

Short-term Detection of Fast Progressors in Glaucoma: The Fast Progression Assessment through Clustered Evaluation (Fast-PACE) Study.

Medeiros Felipe A, Malek Davina A, Tseng Henry, Swaminathan Swarup S, Boland Michael V, Friedman David S et al.

OphthalmologyDec 202312 citationsCohort Study

This study found intensive, clustered glaucoma testing over 6 months effectively identifies fast progressors. This method is valuable for clinical trials and short-term assessment of high-risk patients.